- 期刊
- OpenAccess
The Clinical Outcome of Brain Metastases in Nonsmall Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation- A Retrospective Single-Institution Analysis
摘要
Introduction: Nonsmall cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in many countries. Brain metastases (BM) from NSCLC are poor prognosis, with a median survival of 6 months following whole-brain radiotherapy. NSCLC patients harboring activating epidermal growth factor receptor (EGFR) mutations have generally responded to afatinib with good objective response rate, progression-free survival (PFS), and overall survival (OS), and platinum-double chemotherapy. These findings demonstrate the potential effectiveness of afatinib for the treatment of EGFR-positive with BM. The aim of this retrospective study is to present data on the prognostic effect of afatinib versus gefitinib in an unselected population with newly diagnosed NSCLC with BM collected. Patients and Methods: Data were obtained from our electronic database from 48 patients with newly diagnosed EGFR mutative NSCLC with BM and treated from January 2007 to December 2017, in which data on EGFR mutation was all available at the time of diagnosis. Results: Thirteen of forty-eight were treated with afatinib, and the other was treated with gefitinib. There were seven Exon 19 deletion and six were Exon 21 mutation ([p.Leu858Arg, (c.2573T＞G)]:4; [p.Leu861Gln, (c.2582T＞A)]:2). There was 18 Exon 19 deletion, and 16 were Exon 21 mutation ([p.Leu858Arg, (c.2573T＞G)]:16) and the other one was Exon 18 mutation [p.Gly719Ser (c.2155G＞A)]. There was no significant difference between two groups included PFS (afatinib: 12.0 months vs. gefitinib: 10.1 months, P = 0.766) and OS (afatinib: 20.6 months vs. gefitinib: 14.5 months, P = 0.362). Conclusion: From the K–M survival curve evaluation, neither the PFS nor OS have the statistical significance between gefitinib and afatinib. We provided a real-world data to compare the efficacy of EGFR-TKI in NSCLC. Due to relative small sample size, we urged large clinical trial to provide more precise results.
延伸閱讀
- 陳建宏（2019）。Management of Brain Metastases in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer：A Retrospective Multi-Institutional Analysis〔碩士論文，高雄醫學大學〕。華藝線上圖書館。https://www.airitilibrary.com/Article/Detail?DocID=U0011-1707201915453800
- 向敏齊（2021）。Exploration of Related Factors for Patients with Non-small Cell Lung Cancer After Receiving Cancer-related Treatment Readmission at Emergency Room After Discharging within 14 days〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU202102655
- 王智亮、王美嘉、張仕政、劉秀玲、張璧月（2021）。Investigation of the Mutation Profiles of Circulating Tumor DNAs from Patients with Non-Small Cell Lung Cancer and its Correlation with Targeted Therapy Response。Journal of Biomedical & Laboratory Sciences，33(3)，143-152。https://www.airitilibrary.com/Article/Detail?DocID=10137653-202109-202109300012-202109300012-143-152
- Rao, S., & Xie, C. (2022). Based on the Survival Analysis of Adult Patients with Brain Metastases of Lung Cancer: A Population‐Based Study. World Scientific Research Journal, 8(10), 70-75. https://doi.org/10.6911/WSRJ.202210_8(10).0010
- Choi, H. Y. (2011). Review of clinical benefits and cost effectiveness of epidermal growthfactor receptor-tyrosine kinase inhibitor (EGFR-TKI) as first linetreatment for patients with advanced non-small cell lung cancer(NSCLC) [master's thesis, The University of Hong Kong]. Airiti Library. https://www.airitilibrary.com/Article/Detail?DocID=U0029-1812201200019521